<DOC>
	<DOC>NCT01989910</DOC>
	<brief_summary>A pilot study to compare the efficacy and safety of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection.</brief_summary>
	<brief_title>Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients</brief_title>
	<detailed_description>A single-center, prospective, randomized, open label, parallel study to compare the efficacy and safety of raltegravir-based versus efavirenz-based plus optimal nucleoside reverse-transcriptase inhibitors(NRTIs) backbone combination therapy in treatment-naïve patients with HIV-1 infection.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients who are infected with HIV1 Patients have not yet received any treatment for HIV Patients with HIV viral RNA exceeds 5000 copies per ml Ages at least 20 years Patients with acute or decompensated chronic hepatitis Patients with chronic hepatitis and serum aminotransferase concentrations are more than five times the upper limit of the normal range Patients with renal insufficiency (need dialysis or have serum creatinine concentrations of more than twice the upper limit of the normal range Patients with any medical disorder that the use of study medications is contraindicated Pregnant or breastfeeding women Patients who are lack of expectation to maintain assigned study medication during study period Patients who have received therapy with investigational drugs in the previous 3 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Efavirenz</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Combination antiretroviral therapy</keyword>
</DOC>